Merus NV (MRUS) EUR0.09

Sell:$39.00Buy:$46.32$1.26 (2.77%)

Prices delayed by at least 15 minutes
Sell:$39.00
Buy:$46.32
Change:$1.26 (2.77%)
Deal now
Prices delayed by at least 15 minutes
Sell:$39.00
Buy:$46.32
Change:$1.26 (2.77%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Key people

Sven Ante Lundberg
President, Chief Executive Officer, Executive Director
Gregory D. Perry
Chief Financial Officer
Peter B. Silverman
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Fabian Zohren
Chief Medical Officer
Anand Mehra
Non-Executive Independent Chairman of the Board
Jason Haddock
Director
Maxine Gowen
Non-Executive Independent Director
Mark T. Iwicki
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    MRUS
  • Location
    Netherlands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0011606264
  • Market cap
    $3.06bn
  • Employees
    260
  • Shares in issue
    69.18m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.